These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9445249)

  • 1. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of macrophage-derived mouse ApoE, human ApoE3-Leiden, and human ApoE2 (Arg158-->Cys) on cholesterol levels and atherosclerosis in ApoE-deficient mice.
    Van Eck M; Herijgers N; Van Dijk KW; Havekes LM; Hofker MH; Groot PH; Van Berkel TJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):119-27. PubMed ID: 10634808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis.
    Huang Y; Ji ZS; Brecht WJ; Rall SC; Taylor JM; Mahley RW
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2952-9. PubMed ID: 10591675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chylomicron remnant uptake in the livers of mice expressing human apolipoproteins E3, E2 (Arg158-->Cys), and E3-Leiden.
    Lee SJ; Grosskopf I; Choi SY; Cooper AD
    J Lipid Res; 2004 Dec; 45(12):2199-210. PubMed ID: 15466367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ; van Dijk KW; van't Hof HB; van Gorp PJ; van der Zee A; van der Boom H; Breuer ML; Hofker MH; Havekes LM
    J Biol Chem; 1996 Nov; 271(48):30595-602. PubMed ID: 8940032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
    de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
    Huang Y; Liu XQ; Rall SC; Mahley RW
    J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS; Fazio S; Mahley RW
    J Biol Chem; 1994 May; 269(18):13421-8. PubMed ID: 8175773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
    Gerritsen G; Kypreos KE; van der Zee A; Teusink B; Zannis VI; Havekes LM; van Dijk KW
    J Lipid Res; 2003 Feb; 44(2):408-14. PubMed ID: 12576523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice.
    Mensenkamp AR; van Luyn MJ; van Goor H; Bloks V; Apostel F; Greeve J; Hofker MH; Jong MC; van Vlijmen BJ; Havekes LM; Kuipers F
    J Hepatol; 2000 Aug; 33(2):189-98. PubMed ID: 10952236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very low density lipoprotein receptor binds apolipoprotein E2/2 as well as apolipoprotein E3/3.
    Takahashi S; Oida K; Ookubo M; Suzuki J; Kohno M; Murase T; Yamamoto T; Nakai T
    FEBS Lett; 1996 May; 386(2-3):197-200. PubMed ID: 8647281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.
    Tacken PJ; Beer FD; Vark LC; Havekes LM; Hofker MH; Willems Van Dijk K
    Biochem J; 2000 Apr; 347(Pt 2):357-61. PubMed ID: 10749663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
    Mensenkamp AR; Jong MC; van Goor H; van Luyn MJ; Bloks V; Havinga R; Voshol PJ; Hofker MH; van Dijk KW; Havekes LM; Kuipers F
    J Biol Chem; 1999 Dec; 274(50):35711-8. PubMed ID: 10585451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia.
    van den Maagdenberg AM; Hofker MH; Krimpenfort PJ; de Bruijn I; van Vlijmen B; van der Boom H; Havekes LM; Frants RR
    J Biol Chem; 1993 May; 268(14):10540-5. PubMed ID: 7683682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia.
    Huang Y; Liu XQ; Rall SC; Taylor JM; von Eckardstein A; Assmann G; Mahley RW
    J Biol Chem; 1998 Oct; 273(41):26388-93. PubMed ID: 9756870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice.
    Tsukamoto K; Maugeais C; Glick JM; Rader DJ
    J Lipid Res; 2000 Feb; 41(2):253-9. PubMed ID: 10681409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice.
    Tsukamoto K; Smith P; Glick JM; Rader DJ
    J Clin Invest; 1997 Jul; 100(1):107-14. PubMed ID: 9202062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.
    Post SM; de Roos B; Vermeulen M; Afman L; Jong MC; Dahlmans VE; Havekes LM; Stellaard F; Katan MB; Princen HM
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1551-6. PubMed ID: 10845871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.